Search tips
Search criteria 


Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Med Genet. 2007 July; 44(7): e84.
PMCID: PMC2598016

De novo HRAS and KRAS mutations in two siblings with short stature and neuro‐cardio‐facio‐cutaneous features


Mutations in genes involved in Ras signalling cause Noonan syndrome and other disorders characterised by growth disturbances and variable neuro‐cardio‐facio‐cutaneous features. We describe two sisters, 46 and 31 years old, who presented with dysmorphic features, hypotonia, feeding difficulties, retarded growth and psychomotor retardation early in life. The patients were initially diagnosed with Costello syndrome, and autosomal recessive inheritance was assumed. Remarkably, however, we identified a germline HRAS mutation (G12A) in one sister and a germline KRAS mutation (F156L) in her sibling. Both mutations had arisen de novo. The F156L mutant K‐Ras protein accumulated in the active, guanosine triphosphate‐bound conformation and affected downstream signalling. The patient harbouring this mutation was followed for three decades, and her cardiac hypertrophy gradually normalised. However, she developed severe epilepsy with hippocampal sclerosis and atrophy. The occurrence of distinct de novo mutations adds to variable expressivity and gonadal mosaicism as possible explanations of how an autosomal dominant disease may manifest as an apparently recessive condition.

Keywords: Costello syndrome, cardio‐facio‐cutaneous syndrome, Noonan syndrome, MAPK signalling pathway, Ras genes

Mutations in interacting components of cellular signalling cascades may lead to inherited syndromes that display significant phenotypic overlap. A particularly instructive example is that of the genes associated with the Ras/mitogen‐activated protein kinase (MAPK) pathway. In these genes mainly activating mutations cause a group of clinically related disorders with reduced growth and neuro‐cardio‐facio‐cutaneous anomalies. These genetic diseases include Noonan syndrome (NS),1,2,3,4,5 LEOPARD syndrome,6,7 neurofibromatosis type I (NF1),8,9,10 Costello syndrome (CS)11 and cardio‐facio‐cutaneous (CFC) syndrome.12,13

The clinical diagnosis of a Ras‐related syndrome is often difficult and uncertain, especially in the neonatal period and during infancy. In particular, there are many overlapping features between NS, CS and CFC syndrome. Therefore, in such patients the identification of a mutation in the MAPK pathway not only provides a molecular explanation for the disease, but may also serve to classify it correctly with regard to diagnosis, prognosis and possible complications.

We describe two sisters initially considered to have CS due to autosomal recessive inheritance. Intriguingly, RAS mutational analysis revealed different de novo mutations in these individuals, leading to a re‐evaluation of the diagnosis of the younger sister. This finding allowed us to compare the clinical manifestations of two closely related disorders of the MAPK signalling cascade on the same genetic background and over a time scale of 3–4 decades. Moreover, our data underline the importance of establishing the causative genetic lesion in syndromes with short stature and neuro‐cardio‐facio‐cutaneous features, and raise questions regarding inherited factors in this family that might predispose to the occurrence of offspring with germline RAS gene mutations.


The study procedures were performed according to the Declaration of Helsinki. Written informed consent was obtained from the patients' mother, as was permission to present facial pictures of them. A preliminary clinical description of the two patients has been presented in abstract form by Søvik.14

Molecular genetic studies

DNA samples were available for the five living family members and for the deceased father. A panel of seven highly polymorphic microsatellite markers from four chromosomes was used to check that the genotypes were fully consistent with the samples belonging to two parents and their four children. The coding exons and flanking introns of the HRAS and KRAS genes were amplified by PCR and screened by direct DNA sequencing in all six family members. We found only gene variants listed in the NCBI single nucleotide polymorphism (SNP) database (at except for the two mutations described below. DNA from patient 2 was also sequenced for mutations in the PTPN11 gene, and gave normal results. For patient 1, nested allele‐specific amplification of HRAS exon 2 was obtained using the primer pairs 5′‐TGGGGCCTGGGG/5′‐TATTCGTCCACAAAA and 5′‐TGGGGCCTGGGC/5′‐TATTCGTCCACAAAG, which were specific for SNPs of the maternal and paternal alleles, respectively.15

Biochemical analysis of the F156L K‐Ras mutant protein

The Ras‐guanosine triphosphate (GTP) assay and immunoblotting have been described previously.2 Briefly, we transiently transfected COS‐7 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA) with pDEST12.2 vectors (Invitrogen) encoding normal, F156L or G12D K‐Ras mutant proteins. The cell medium was Dulbecco's modified Eagle's medium‐H21 containing 10% fetal bovine serum; 24 hours after transfection, the serum concentration was reduced to 0.1% by changing the medium for starvation conditions or left unchanged for basal conditions. The cells were lysed and Ras‐GTP levels measured using Raf‐1 RBD agarose (Upstate, Charlottesville, Virginia, USA). The antibodies used for immunoblotting were anti‐Pan‐Ras (Ab‐3) (Calbiochem, San Diego, California, USA), anti‐phospho‐MEK1/2 (Ser217/221) and anti‐MEK1/2 (both from Cell Signaling Technology, Danvers, Massachusetts, USA).


Family history

Figure 1A1A shows the family pedigree. The parents were healthy and non‐consanguineous with no known inherited diseases on either side. The father died at 68 years of age from multiple myeloma. One girl (II:1) was born prematurely after 29 weeks of gestation and died a few hours later. The mother had two spontaneous abortions, one in week 16 (II:2, male fetus) and another in week 10 (II:6, sex unknown). The affected sisters have two healthy brothers, born at term with birth weights of around 4.2 and 4.4 kg. The final heights of the father and mother were 186 cm and 176 cm, respectively.

figure mg49361.f1
Figure 1 HRAS and KRAS mutations in two sisters with Costello syndrome (CS) and cardio‐facio‐cutaneous (CFC) syndrome. (A) Family pedigree; diamonds indicate miscarriages, slashes indicate deceased family members. The current age ...

Clinical findings in patient 1

This patient (II:3 in fig1Afig1A)) was born in 1961, 6 weeks preterm after a normal pregnancy. Her birth weight was 3950 g (>97.5th centile), length 50 cm (>97.5th centile), and head circumference 35.5 cm (90–97.5th centile). In the first year of life, pronounced hypotonia and severe feeding difficulties with persistent vomiting caused recurrent hospitalisations and necessitated an orogastric tube. A cardiac murmur was detected at the age of 5 months. Increased skin pigmentation was also noted. By the age of 1 year, psychomotor retardation was obvious, and nystagmus and a hoarse cry were noted. Coarse facial features and loose skin suggested Hurler syndrome, which was excluded by biochemical analysis. At the age of 2 years, the child could stand with support and express a few words. The cardiac murmur persisted, but there was no evidence of cardiac enlargement or hypertrophy. High‐grade myopia was detected at 5 years of age. The patient fractured her femoral neck after a fall at the age of 16 years. She had her first menstrual bleed when she was 19 years old. Four asymptomatic, low‐grade papillary bladder carcinomas were removed at 44 years of age.

The patient has always had curly hair and pronounced skin changes resembling acanthosis nigricans. Her hair is now sparse and she has no body hair. She has numerous papillomas/warts on the face. Histological examination of one of these showed hyperplastic squamous epithelium with hyperkeratosis, but no malignancy. The skin changes were progressive with increased pigmentation and formation of papillomas, which have regularly been removed by cryotherapy. These and other clinical features summarised in table 11 were highly suggestive of CS.16 At 39 years of age, the patient's height was 153 cm (<2.5th centile), weight 58 kg (>97.5th centile related to height) and head circumference 56 cm (50–75th centile). She is considered moderately mentally disabled with a warm and social personality.

Table thumbnail
Table 1 Clinical features in sisters with Costello syndrome and cardio‐facio‐cutaneous syndrome due to activating HRAS and KRAS germline mutations

Clinical findings in patient 2

This patient (II:7 in fig 1A1A)) was born at term in 1976 after a normal pregnancy. Her birth weight was 4800 g (>97.5th centile), length 55 cm (>97.5th centile), and head circumference 36 cm (75th centile). She also had hypotonia and feeding problems as a newborn, but not as severely as her older sister. At the age of 4 months, an enlarged liver and a cardiac murmur were detected. Cardiac catheterisation revealed obstructive cardiomyopathy. Echocardiography showed asymmetrical left ventricular hypertrophy with more pronounced involvement of the intraventricular septum than of the posterior wall. The patient subsequently developed marked mitral valve abnormalities with long, thickened leaflets and mitral prolapse, but no mitral regurgitation. A liver biopsy showed increased fat content, but was otherwise normal. At 4 years of age, the patient developed epileptic seizures, and was treated with anticonvulsant medication. At 9 years of age, a CT scan showed slight cerebral atrophy. At 13 years of age, an electroencephalogram revealed generalised slowing indicative of a generalised encephalopathy. A skin biopsy showed hyperkeratosis and acanthosis at the extensor surfaces of the arms. Her first menstrual bleed occurred when she was 16 years old. At 24 years of age, her height was 157 cm (2.5–10th centile), weight 41 kg (10–25th centile related to height), and head circumference 56 cm (50–75th centile).

This patient is considered as mentally disabled as her sister, with the same warm and social personality. Intriguingly, over the years, her cardiac disorder has regressed considerably and the intraventricular septum hypertrophy has resolved (fig 22).). Her main clinical problem is epilepsy, with 12–14 complex partial seizures per month, partly as clusters over a few days, and secondary generalised tonic–clonic seizures once a year. She had a convulsive status epilepticus at 26 years of age. Brain MRI showed gliosis and atrophy of the right hippocampus (fig 33).). Overall, we consider the clinical features (table 11)) most compatible with CFC syndrome.17

figure mg49361.f2
Figure 2 Normalisation of the cardiac hypertrophy in patient 2. The thickness (broken line) of intraventricular septum (IVS) was measured by echocardiography in patient 2 at different ages. For comparison, normal values for different ages are ...
figure mg49361.f3
Figure 3 Structural abnormalities of the brain in patient 2 revealed by MRI. Coronal T2‐weighted images through the hippocampus in patients 1 and 2 at the ages of 29 and 45 years, respectively, are compared. For patient 2, a fluid‐attenuated ...

Molecular and biochemical studies

As stated, the clinical features of patient 1 were highly suggestive of CS. Based on a report demonstrating germline HRAS mutations in most patients with CS,11 we examined DNA from patient 1. In HRAS exon 2 we found a heterozygous nucleotide substitution, 35G→C, which changes glycine to alanine at amino acid position 12 (G12A) (fig 1B1B).). The mutation occurred on the paternal HRAS allele, and we verified that it was not present in either parent or in the brothers, thus it was a de novo mutation. The HRAS mutation identified in patient 1 has been reported in other patients with CS.11,18,19,20 It is also a rare somatic alteration in cancer,21,22 but has to our knowledge not been reported for bladder carcinomas. The G12A H‐Ras substitution alters the phosphate‐binding loop of the protein, transforms cultured Rat1 cells, and is predicted to decrease intrinsic Ras GTPase activity.23,24

Surprisingly, patient 2 did not have the same HRAS mutation as her sister. We instead detected a de novo, heterozygous 466T→C nucleotide substitution in exon 4B of the KRAS gene (fig 1B1B),), leading to a change of phenylalanine with leucine at amino acid position 156 (F156L). In this case, we were unable to determine the germline origin (maternal or paternal) of the mutation as more than 10 kb of sequenced genomic DNA around exon 4B did not contain any informative polymorphisms.

A previous study of the F156L substitution in H‐Ras revealed a rapid rate of guanine nucleotide dissociation and a modest increase in Ras‐GTP levels in NIH 3T3 cells.25 To assess the functional impact of this amino acid substitution in K‐Ras, we expressed wild‐type K‐Ras, F156L K‐Ras, or oncogenic G12D K‐Ras protein in COS‐7 monkey kidney cells. F156L K‐Ras accumulated in the active, GTP‐bound conformation in COS‐7 cells that were cultured in serum and after 7 hours of serum deprivation (fig 44).). In addition, F156L K‐Ras expression resulted in elevated levels of phosphorylated MEK in these cells.

figure mg49361.f4
Figure 4 Biochemical analysis of the F156L KRAS mutation of patient 2. COS‐7 cells were transiently transfected with plasmids encoding normal K‐Ras protein (WT), F156L K‐Ras protein, a known oncogenic K‐Ras protein ...


Two de novo mutations: connection or coincidence?

We describe the unexpected and challenging finding of distinct de novo RAS mutations in two growth‐retarded sisters with overlapping but non‐identical neuro‐cardio‐facio‐cutaneous features. The similar clinical pictures of the patients initially suggested that they had inherited the same condition, with the phenotypic differences being due to variable expressivity. We assumed recessive inheritance because both parents and their respective families were unaffected and because chromosome analyses, including high‐resolution comparative genomic hybridisation, were normal. Alternatively, one of the parents could have been a gonadal mosaic for a dominant condition.26,27

It was therefore extraordinary to discover different, de novo RAS mutations in the siblings, a finding that, together with two spontaneous abortions and the birth of a premature child, might suggest an unusual mutational predisposition in the kindred. Biological material from the unsuccessful pregnancies, which could have elucidated this hypothesis by further mutation analyses, was not available. Thorough questioning of the family did not reveal any predisposition to cancer or other diseases in the parents and their relatives. Furthermore, the parents had no history of exposure to environmental risk factors such as chemicals or radiation.

The father was 21–39 years old at the seven conceptions, indicating that his age did not strongly influence the mutation probability.28,29 In sporadic cases of NS29 and NF1,30 and in other dominant diseases where de novo mutations are seen,28 the genetic alterations preferentially occur on the paternal allele. This appears also to be the case for CS15,31 and was confirmed for the HRAS mutation of patient 1. However, we were unable to determine the parental origin of the KRAS mutation.


  • Mutations in genes of the Ras/MAPK signalling cascade cause syndromes characterised by short stature and neuro‐cardio‐facio‐cutaneous anomalies.
  • We report the molecular analysis and long‐term clinical follow‐up of two sisters, both initially diagnosed with CS.
  • Surprisingly, the siblings had independent, de novo mutations in the HRAS and KRAS genes. The mutant K‐Ras protein accumulated in the active, GTP‐bound conformation and affected downstream signalling.
  • The clinical diagnosis of the sister with KRAS mutation was changed to CFC syndrome. This patient had hypertrophic cardiomyopathy, which over the years has completely resolved. She experienced increasing problems with epilepsy, and a structural brain abnormality was noted.
  • Distinct de novo mutations in siblings with phenotypic overlap is a possible, although extraordinary, explanation of how an autosomal dominant disease may masquerade as an apparently recessive condition.

In summary, we could not establish an underlying risk factor in our pedigree. It is nevertheless conceivable that RAS mutations are relatively common in spermatogenesis but normally not transmitted due to cell‐cycle control mechanisms. Disruption of a critical “checkpoint” protein that is activated in response to aberrant Ras signalling in developing male gametes might then explain the existence of affected siblings with independent de novo RAS mutations. If male germ cell progenitors that acquire a RAS mutation obtain a proliferative or survival advantage similar to that inferred by oncogenic Ras proteins, an increased incidence of such mutations might also be expected. Notably, a selective advantage of the mutated germ cells has been suggested for mutations in the FGFR2 gene.32,33

Clinical considerations

The two patients presented variations of the same features, but only the phenotype of patient 1 was fully consistent with CS. Distinguishing features are accelerated intrauterine growth followed by postnatal growth retardation, pronounced neonatal feeding difficulties, an appearance suggestive of a mucopolysaccharidosis, psychomotor retardation, coarse facial features, loose and hyperpigmented skin, and at a later stage the development of numerous facial papillomas and bladder cancer.16,18,19,20

As germline KRAS mutations have been reported almost exclusively in individuals with NS or CFC syndrome,2,3,12,34 the molecular analysis of patient 2 required a revision of her initial clinical diagnosis. High birth weight, coarse facial features, skin changes and mental retardation are uncommon in NS, whereas feeding problems in infancy are often noted. For CFC syndrome, feeding problems are not a characteristic feature, but such cases have been described.35 A general finding in CFC syndrome is sparse and curly hair, a feature not observed in patient 2. However, she did have other signs of ectodermal dysplasia (brittle nails, hyperkeratosis on the extensor surfaces of the extremeties). Both her epilepsy and moderate degree of psychomotor retardation are more compatible with CFC syndrome than NS. Hypertrophic cardiomyopathy is commonly associated with NS, but is also often noted in CFC patients.17 Taken together, a CFC syndrome diagnosis seems most warranted for patient 2.

The KRAS mutation found in patient 2 was recently observed in a single patient (male, aged 14 months) of the large cohort studied by Zenker et al.34 This case, too, had hypertrophic cardiomyopathy and a structural anomaly of the brain (Dandy–Walker malformation), but not increased birth weight. In a second patient (male, aged 8.5 years) from the same cohort, a different amino acid substitution of the same K‐Ras position was found (F156I). This case did show increased birth weight, but neither heart defects nor brain abnormalities were reported.

Patient 2 has been followed up for 31 years. By monitoring her cardiac function, we were able to show that the intraventricular septum hyperthrophy gradually resolved as she grew older (fig 22).). She currently has no obvious cardiac symptoms. To our knowledge, complete normalisation of cardiac hypertrophy associated with CFC syndrome or NS has not previously been reported.

In contrast to the disappearance of the cardiac symptoms, the neurological problems of patient 2 have gradually worsened. The severity of epilepsy has increased, and MRI provides a structural correlate for this development (fig 33).). The brain of patient 1, however, appears structurally normal, and she has not had epileptic seizures. Dysfunction of the Ras/MAPK pathway is probably relevant in explaining both mental retardation and epilepsy in patients with neuro‐cardio‐facio‐cutaneous features. All key elements of the Ras signalling cascade, which has a central role in regulating cell growth and differentiation, are present in the brain, and the MAPK pathway is also linked to neurological functions such as synaptic and behavioral plasticity.36 In the hippocampus, for example, both long‐term potentiation of synaptic transmission and protein kinase modulation of dendritic K+ channels involve ERK activation.37,38 The fact that epilepsy and hippocampal atrophy with sclerosis was associated with a KRAS and not with an HRAS mutation in our family is interesting, as there appears to be a striking difference in K‐Ras and H‐Ras dynamics in hippocampal neurons, mediated by their distinct membrane‐anchoring motifs.39

Functional studies of the F156L K‐Ras mutation

The mutation of patient 2 was tested in a cellular model system (fig 44).). K‐Ras F156L accumulates in the active, GTP‐bound conformation and induces elevated levels of phosphorylated MEK in COS‐7 cells. The identical amino acid substitution in H‐Ras causes a markedly increased rate of guanine nucleotide exchange.25 Because the concentration of GTP far exceeds that of GDP in living cells, mutations that increase the rate of guanine nucleotide exchange are predicted to increase Ras‐GTP levels. The amino terminal end (amino acids 1–165) of H‐Ras, K‐Ras, and N‐Ras comprise a highly conserved G domain that has a common structure and switch mechanism, and it is therefore likely that the biochemical properties of F156L K‐Ras are similar to those of the H‐Ras mutant protein. Interestingly, germline SOS1 mutations that encode proteins with elevated guanine nucleotide exchange activity were recently found in about 10% of patients with NS.4,5 Direct analysis of intrinsic GTP hydrolysis rates, responsiveness to GTPase‐activating proteins, and guanine nucleotide binding and dissociation by recombinant F156L K‐Ras is required to fully characterise the biochemical consequences of this mutant protein.

Genotype–phenotype correlations

The discovery that neurofibromin‐1 (NF1) is a GTPase‐activating protein provided the first direct evidence implicating aberrant Ras signalling in a human developmental disorder.40 Subsequently, Tartaglia and coworkers reported that point mutations in the PTPN11 gene cause about half the cases of NS.1,41 The recent identification of mutations in HRAS, KRAS, BRAF, MEK and SOS1 in patients with CS, NS and CFC syndrome2,4,5,11,12,13 then provided a unifying mechanism for the similarities of syndromes with short stature and neuro‐cardio‐facio‐cutaneous anomalies. However, CS and CFC syndrome are generally associated with mental retardation, whereas patients with NS or NF1 tend to be intellectually normal, although they often have learning difficulties. These data suggest that the clinical phenotypes of individual patients will be influenced by the precise molecular lesion and how each perturbs the degree and duration of Ras signalling in various tissues.

Our data highlight the importance of molecular testing to reveal the underlying genetic mechanism in congenital disorders of the MAPK pathway. Such information can be helpful in prognostic evaluation and reproductive decisions, and may guide future medical management and educational placement of the patients. Moreover, risk for the development of malignancies can be more adequately evaluated (higher for PTNP11, NF1 and, in particular, HRAS mutations; probably lower for the others). Intriguingly, cancer‐associated HRAS mutations that impair intrinsic Ras GTPase activity and confer resistance to GTPase‐activating proteins are tolerated in the embryo, as they are common in CS, whereas the germline KRAS mutations detected to date are generally not found in cancer. Molecular and clinical dissection of syndromes of the NS spectrum may therefore add to our understanding of how the components of Ras signalling act as oncoproteins in tumorigenesis. Finally, the surprising molecular findings in our family demonstrate that distinct de novo mutations in siblings with phenotypic overlap is a possible explanation of how a dominant disease may manifest as an apparently recessive condition.


We are indebted to the patients and their mother for participating in the study and to the staff at Haukeland University Hospital for providing care and follow‐up of the patients. We also thank Professor Helge Boman and Dr Ingfrid S. Haldorsen for valuable discussions of the manuscript.


CFC - cardio‐facio‐cutaneous

CS - Costello's syndrome

GTP - guanosine triphosphate

MAPK - mitogen‐activated protein kinase

NF1 - neurofibromatosis type 1

NS - Noonan's syndrome

SNP - single nucleotide polymorphism


Funding: This work was supported by grants from the Research Council of Norway and the Meltzer Foundation to O Søvik, from Helse Vest and the University of Bergen to A Molven and P R Njølstad, and by NIH grants R01 CA72614 and R01 CA104282 to K Shannon.

Competing interests: None declared.

*The second and third authors contributed equally to this work.

Parental informed consent was obtained for publication of figure 11.


1. Tartaglia M, Mehler E L, Goldberg R, Zampino G, Brunner H G, Kremer H, van der Burgt I, Crosby A H, Ion A, Jeffery S, Kalidas K, Patton M A, Kucherlapati R S, Gelb B D. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP‐2, cause Noonan syndrome. Nat Genet 2001. 29465–468.468 [PubMed]
2. Schubbert S, Zenker M, Rowe S L, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner L E, Nguyen H, West B, Zhang K Y, Sistermans E, Rauch A, Niemeyer C M, Shannon K, Kratz C P. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006. 38331–336.336 [PubMed]
3. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb B D, Tartaglia M. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 2006. 79129–135.135 [PubMed]
4. Roberts A E, Araki T, Swanson K D, Montgomery K T, Schiripo T A, Joshi V A, Li L, Yassin Y, Tamburino A M, Neel B G, Kucherlapati R S. Germline gain‐of‐function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007. 3970–74.74 [PubMed]
5. Tartaglia M, Pennacchio L A, Zhao C, Yadav K K, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry C J, Siguero J P, Digilio M C, Zampino G, Dallapiccola B, Bar‐Sagi D, Gelb B D. Gain‐of‐function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007. 3975–79.79 [PubMed]
6. Digilio M C, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B. Grouping of multiple‐lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002. 71389–394.394 [PubMed]
7. Legius E, Schrander‐Stumpel C, Schollen E, Pulles‐Heintzberger C, Gewillig M, Fryns J P. PTPN11 mutations in LEOPARD syndrome. J Med Genet 2002. 39571–574.574 [PMC free article] [PubMed]
8. Wallace M R, Marchuk D A, Andersen L B, Letcher R, Odeh H M, Saulino A M, Fountain J W, Brereton A, Nicholson J, Mitchell A L. et al Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990. 249181–186.186 [PubMed]
9. Viskochil D, Buchberg A M, Xu G, Cawthon R M, Stevens J, Wolff R K, Culver M, Carey J C, Copeland N G, Jenkins N A. et al Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990. 62187–192.192 [PubMed]
10. De Luca A, Bottillo I, Sarkozy A, Carta C, Neri C, Bellacchio E, Schirinzi A, Conti E, Zampino G, Battaglia A, Majore S, Rinaldi M M, Carella M, Marino B, Pizzuti A, Digilio M C, Tartaglia M, Dallapiccola B. NF1 gene mutations represent the major molecular event underlying neurofibromatosis‐Noonan syndrome. Am J Hum Genet 2005. 771092–1101.1101 [PubMed]
11. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. Germline mutations in HRAS proto‐oncogene cause Costello syndrome. Nat Genet 2005. 371038–1040.1040 [PubMed]
12. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam R C, Gillessen‐Kaesbach G, Wieczorek D, Kavamura M I, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y. Germline KRAS and BRAF mutations in cardio‐facio‐cutaneous syndrome. Nat Genet 2006. 38294–296.296 [PubMed]
13. Rodriguez‐Viciana P, Tetsu O, Tidyman W E, Estep A L, Conger B A, Cruz M S, McCormick F, Rauen K A. Germline mutations in genes within the MAPK pathway cause cardio‐facio‐cutaneous syndrome. Science 2006. 3111287–1290.1290 [PubMed]
14. Søvik O. Siblings with mental retardation, cardiomyopathy, dysmorphic features, increased skin pigmentation, and a peculiar odor. Proceedings of the 30th Annual Symposium of the Society for the Study of Inborn Errors in Metabolism, Leuven, Belgium 1992. 237
15. Sol‐Church K, Stabley D L, Nicholson L, Gonzalez I L, Gripp K W. Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat 2006. 27736–741.741 [PubMed]
16. Costello J M. Costello syndrome: update on the original cases and commentary. Am J Med Genet 1996. 62199–201.201 [PubMed]
17. Roberts A, Allanson J, Jadico S K, Kavamura M I, Noonan J, Opitz J M, Young T, Neri G. The cardiofaciocutaneous syndrome. J Med Genet 2006. 43833–842.842 [PMC free article] [PubMed]
18. Gripp K W, Lin A E, Stabley D L, Nicholson L, Scott C I, Jr, Doyle D, Aoki Y, Matsubara Y, Zackai E H, Lapunzina P, Gonzalez‐Meneses A, Holbrook J, Agresta C A, Gonzalez I L, Sol‐Church K. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 2006. 1401–7.7 [PubMed]
19. Estep A L, Tidyman W E, Teitell M A, Cotter P D, Rauen K A. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild‐type allele in malignancy. Am J Med Genet A 2006. 1408–16.16 [PubMed]
20. Kerr B, Delrue M A, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden O B, O'Sullivan J, De Sandre‐Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cave H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G. Genotype‐phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 2006. 43401–405.405 [PMC free article] [PubMed]
21. Suarez H G, du Villard J A, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990. 5565–570.570 [PubMed]
22. Sakamoto A, Oda Y, Adachi T, Oshiro Y, Tamiya S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M. H‐ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction‐restriction fragment length polymorphism analysis. Mod Pathol 2001. 14343–349.349 [PubMed]
23. Seeburg P H, Colby W W, Capon D J, Goeddel D V, Levinson A D. Biological properties of human c‐Ha‐ras1 genes mutated at codon 12. Nature 1984. 31271–75.75 [PubMed]
24. Colby W W, Hayflick J S, Clark S G, Levinson A D. Biochemical characterization of polypeptides encoded by mutated human Ha‐ras1 genes. Mol Cell Biol 1986. 6730–734.734 [PMC free article] [PubMed]
25. Quilliam L A, Zhong S, Rabun K M, Carpenter J W, South T L, Der C J, Campbell‐Burk S. Biological and structural characterization of a Ras transforming mutation at the phenylalanine‐156 residue, which is conserved in all members of the Ras superfamily. Proc Natl Acad Sci U S A 1995. 921272–1276.1276 [PubMed]
26. Lazaro C, Ravella A, Gaona A, Volpini V, Estivill X. Neurofibromatosis type 1 due to germ‐line mosaicism in a clinically normal father. N Engl J Med 1994. 3311403–1407.1407 [PubMed]
27. Lurie I W. Genetics of the Costello syndrome. Am J Med Genet 1994. 52358–359.359 [PubMed]
28. Crow J F. The origins, patterns and implications of human spontaneous mutation. Nat Rev Genet 2000. 140–47.47 [PubMed]
29. Tartaglia M, Cordeddu V, Chang H, Shaw A, Kalidas K, Crosby A, Patton M A, Sorcini M, van der Burgt I, Jeffery S, Gelb B D. Paternal germline origin and sex‐ratio distortion in transmission of PTPN11 mutations in Noonan syndrome. Am J Hum Genet 2004. 75492–497.497 [PubMed]
30. Stephens K, Kayes L, Riccardi V M, Rising M, Sybert V P, Pagon R A. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 1992. 88279–282.282 [PubMed]
31. Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, Neri C, Pogna E A, De Feo E, Delogu A, Sarkozy A, Atzeri F, Selicorni A, Rauen K A, Cytrynbaum C S, Weksberg R, Dallapiccola B, Ballabio A, Gelb B D, Neri G, Tartaglia M. Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 2007. 28265–272.272 [PubMed]
32. Glaser R L, Broman K W, Schulman R L, Eskenazi B, Wyrobek A J, Jabs E W. The paternal‐age effect in Apert syndrome is due, in part, to the increased frequency of mutations in sperm. Am J Hum Genet 2003. 73939–947.947 [PubMed]
33. Goriely A, McVean G A, Röjmyr M, Ingemarsson B, Wilkie A O. Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 2003. 301643–646.646 [PubMed]
34. Zenker M, Lehmann K, Schulz A L, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss‐Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante A S, Raskin S, Schnabel D, Wehner L E, Kratz C P, Horn D, Kutsche K. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007. 44131–135.135 [PMC free article] [PubMed]
35. Grebe T A, Clericuzio C. Neurologic and gastrointestinal dysfunction in cardio‐facio‐cutaneous syndrome: identification of a severe phenotype. Am J Med Genet 2000. 95135–143.143 [PubMed]
36. Thomas G M, Huganir R L. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004. 5173–183.183 [PubMed]
37. English J D, Sweatt J D. A requirement for the mitogen‐activated protein kinase cascade in hippocampal long term potentiation. J Biol Chem 1997. 27219103–19106.19106 [PubMed]
38. Yuan L L, Adams J P, Swank M, Sweatt J D, Johnston D. Protein kinase modulation of dendritic K+ channels in hippocampus involves a mitogen‐activated protein kinase pathway. J Neurosci 2002. 224860–4868.4868 [PubMed]
39. Fivaz M, Meyer T. Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca2+/calmodulin. J Cell Biol 2005. 170429–441.441 [PMC free article] [PubMed]
40. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001. 104593–604.604 [PubMed]
41. Tartaglia M, Gelb B D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 2005. 645–68.68 [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group